Fluoxetine-rivastigmine-Cpd8
IC50 hAChE 0.34 +/- 0.04 microM; IC50 hBChE 6.59 +/- 0.38 microM
General
Type : Drug, Pro-Drug, Carbamate, Derivative of Rivastigmine, Stigmine, Multitarget, Sodium:neurotransmitter symporter
Chemical_Nomenclature : 3-[(1S)-1-(Dimethylamino)ethyl]phenyl N-Methyl-N-{3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}carbamate
Canonical SMILES : C[C@@H](C1=CC(=CC=C1)OC(=O)N(C)CCC(C2=CC=CC=C2)OC3=CC=C(C=C3)C(F)(F)F)N(C)C
InChI : InChI=1S\/C28H31F3N2O3\/c1-20(32(2)3)22-11-8-12-25(19-22)36-27(34)33(4)18-17-26(21-9-6-5-7-10-21)35-24-15-13-23(14-16-24)28(29,30)31\/h5-16,19-20,26H,17-18H2,1-4H3\/t20-,26?\/m0\/s1
InChIKey : KHZXZZLDUCKCLO-DQUNLGLBSA-N
Other name(s) : Compound 8 || SCHEMBL8204423 || [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]carbamate
MW : 500.6
Formula : C28H31F3N2O3
CAS_number :
PubChem : 25175796'
UniChem : KHZXZZLDUCKCLO-DQUNLGLBSA-N
Target
Families : Fluoxetine-rivastigmine-Cpd8 ligand of proteins in family
ACHE
Protein :
human-ACHE
References (1)
| Title : Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease - Travers-Lesage_2026_ACS.Chem.Neurosci__ |
| Author(s) : Travers-Lesage V , Since M , Wang A , Davis A , Fayolle D , Bernay B , Modeste F , Nachon F , Brazzalotto X , Crouzier L , Sopkova-de Oliveira Santos J , Maurice T , Dallemagne P , Rochais C |
| Ref : ACS Chem Neurosci , : , 2026 |
| Abstract : |
| PubMedSearch : Travers-Lesage_2026_ACS.Chem.Neurosci__ |
| PubMedID: 41972598 |